Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00838396 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease
A Phase 2 study, sponsored by Indivior.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00838396 is a Phase 2 study that has completed, run by Indivior. The registered enrollment target is 58 participants.
The verdict
NCT00838396, a Phase 2 study, has completed, sponsored by Indivior.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.
Interventions
- DRUG XP19986 CR
- DRUG Placebo for XP19986 CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00838396
The ClinicalTrials.gov registry entry for NCT00838396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indivior, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XP19986 CR is the first listed.
NCT00838396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00838396 about?
NCT00838396 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease". The purpose of the study is to evaluate the efficacy and safety of arbaclofen placarbil (XP19986) compared to placebo in patients with gastroesophageal reflux disease.
What is the current status of trial NCT00838396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2005-10. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00838396?
The interventions under investigation include: XP19986 CR (DRUG), Placebo for XP19986 CR (DRUG).
Who is sponsoring clinical trial NCT00838396?
This trial is sponsored by Indivior, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.